Pill Identifier App

Allergan Reports Third Quarter Operating Results

IRVINE, Calif.--(BUSINESS WIRE)--Nov 6, 2007 - Allergan, Inc. (NYSE:AGN) today announced operating results for the quarter ended September 28, 2007. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2007 to stockholders of record on November 9, 2007.

Operating Results

For the quarter ended September 28, 2007:

-- Allergan reported $0.50 diluted earnings per share from continuing operations compared to $0.35 diluted earnings per share reported for the third quarter of 2006.

-- Allergan's adjusted diluted earnings per share from continuing operations were $0.58 in the third quarter of 2007, compared to adjusted diluted earnings per share of $0.47 in the third quarter of 2006, a 23.4% year-over-year increase. Adjusted diluted earnings per share for the third quarters of 2007 and 2006 exclude the non-GAAP adjustments to diluted earnings per share that are contained in the financial tables of this press release.

Product Sales

For the quarter ended September 28, 2007:

-- Allergan's total product net sales were $978.7 million. Total product net sales increased 23.6 percent, or 20.9 percent at constant currency, compared to total product net sales in the third quarter of 2006. -0-

        -- Total specialty pharmaceuticals net sales increased 16.1

           percent, or 13.4 percent at constant currency, compared to

           total specialty pharmaceuticals net sales in the third

           quarter of 2006.


        -- Total core medical devices net sales increased 66.0

           percent, or 62.7 percent at constant currency, compared to

           total core medical devices net sales in the third quarter

           of 2006.

"Allergan operates in a wide range of exceptionally high growth global medical device and specialist biopharmaceutical markets where we play a market leadership role with many innovative products. These dynamics have led to another quarter of superb sales and earnings growth," said David E.I. Pyott, Allergan's Chairman of the Board and Chief Executive Officer. "Furthermore, beyond these current opportunities, recently supplemented by the FDA approval of COMBIGAN(TM), our vigorous investment into R&D as well as our entry into urologics should fuel additional growth over the long-term."

Product and Pipeline Update

During the third quarter of 2007:

-- In July 2007, Apotex filed a Petition for Writ of Certiorari in the United States Supreme Court regarding the affirmation by the United States Court of Appeals for the Federal Circuit of the district court's ruling in favor of Allergan and Roche Palo Alto, LLC, formerly known as Syntex (U.S.A.) LLC, in a patent infringement lawsuit against Apotex, Inc., Apotex Corp., and Novex Pharma (the "Defendants"). The district court's ruling prevents the Defendants, together with all persons and entities acting in concert with the Defendants, from obtaining U.S. Food and Drug Administration (FDA) approval to market a generic version of Allergan's product ACULAR(R) (ketorolac tromethamine ophthalmic solution) 0.5% and enjoins the Defendants from manufacturing or selling their product before U.S. Patent No. 5,110,493 expires in 2009. On October 1, 2007, the Supreme Court of the United States denied Apotex's Petition for Writ of Certiorari.

-- In August 2007, in connection with our settlement of certain European litigation with Merz, we granted Merz a global, royalty-bearing license for patents and patent applications relating to a neurotoxic component of botulinum toxin of any serotype for all therapeutic and aesthetic uses, except for any genitourinary, gastrointestinal and prostate diseases, hyperhidrosis and headache. We believe the value of our botulinum toxin patent estate is demonstrated by the Merz license, as well as the license previously granted to Elan Corporation, which was subsequently sold by Elan to Solstice Neurosciences.

-- On September 19, 2007, Allergan announced that Allergan and Esprit Pharma Holding Company, Inc. entered into an agreement pursuant to which Allergan would acquire privately held Esprit Pharma, Inc. (Esprit) for approximately $370 million in an all-cash transaction. On October 17, 2007, Allergan announced that it completed the Esprit acquisition and will commence the integration of Esprit into Allergan. The Esprit acquisition supports Allergan's U.S. growth strategy and demonstrates Allergan's focus on strengthening its core pharmaceutical businesses by creating a dedicated urologics division to serve urologists and their patients.

-- Allergan and Stiefel Laboratories, Inc. entered into a strategic collaboration to develop and market new products involving Tazarotene for dermatological use worldwide, and to co-promote TAZORAC(R) in the United States, further strengthening and expanding Allergan's reach into the dermatology market.

Following the end of the third quarter of 2007:

-- On October 31, 2007, Allergan announced that the U.S. Food and Drug Administration approved COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Discontinued Operations

On July 2, 2007, Allergan and Croma-Pharma completed the sale of the ophthalmic surgical business that Allergan obtained in connection with its January 2007 acquisition of Groupe Corneal Laboratoires. The first and second quarters of 2007 have been retrospectively revised for the discontinued operations associated with this sale and are contained in the financial tables of this press release.

Outlook

For the full year of 2007:

-- Allergan is increasing guidance as follows: -0-

        -- Total product net sales to between $3,775 million and

           $3,820 million.


        -- Total specialty pharmaceuticals net sales to between $3,045

           million and $3,055 million. Total specialty pharmaceuticals

           net sales exclude sales of products acquired in connection

           with the Inamed, Corneal and EndoArt acquisitions.


        -- ALPHAGAN(R) Franchise product net sales to between $320

           million and $330 million.


        -- BOTOX(R) product net sales to between $1,185 million and

           $1,195 million.


        -- Obesity intervention product net sales to between $260

           million and $275 million.


        -- Facial aesthetics product net sales to between $185 million

           and $195 million.


        -- Selling, General and Administrative ratio to product net

           sales guidance to between 41% and 42%.

-- Allergan is tightening the expected guidance range as follows: -0-

        -- LUMIGAN(R) Franchise product net sales to between $380

           million and $390 million.


        -- RESTASIS(R) product net sales to between $330 million and

           $340 million.


        -- Breast aesthetics product net sales to between $285 million

           and $295 million.

-- Allergan estimates full year adjusted diluted earnings per share from continuing operations of between $2.14 and $2.15, which assumes approximately $0.04 of dilution per share resulting from the Esprit acquisition. Adjusted diluted earnings per share guidance excludes the non-GAAP adjustments to diluted earnings per share guidance that are contained in the financial tables of this press release.

-- All other guidance provided on August 1, 2007 remains unchanged.

For the fourth quarter of 2007, Allergan estimates:

-- Total product net sales between $975 million and $1,020 million.

-- Adjusted diluted earnings per share from continuing operations guidance of between $0.56 and $0.57, which assumes approximately $0.04 of dilution per share resulting from the Esprit acquisition. Adjusted diluted earnings per share guidance excludes the non-GAAP adjustments to diluted earnings per share guidance that are contained in the financial tables of this press release.

All references in this press release to average number of shares outstanding and per share amounts have been retrospectively revised to reflect the two-for-one stock split effected in the form of a stock dividend payable on June 22, 2007 to stockholders of record on June 11, 2007.

Forward-Looking Statements

In this press release, the statements regarding product development, market potential, expected growth, the statements by Mr. Pyott as well as the outlook for Allergan's earnings per share and revenue forecasts, among other statements above, are forward-looking statements. Because forecasts are inherently estimates that cannot be made with precision, Allergan's performance at times differs materially from its estimates and targets, and Allergan often does not know what the actual results will be until after a quarter's end and year's end. Therefore, Allergan will not report or comment on its progress during a current quarter except through public announcement. Any statement made by others with respect to progress during a current quarter cannot be attributed to Allergan.

Any other statements in this press release that refer to Allergan's expected, estimated or anticipated future results are forward-looking statements. All forward-looking statements in this press release reflect Allergan's current analysis of existing trends and information and represent Allergan's judgment only as of the date of this press release. Actual results may differ materially from current expectations based on a number of factors affecting Allergan's businesses, including, among other things, changing competitive, market and regulatory conditions; the timing and uncertainty of the results of both the research and development and regulatory processes; domestic and foreign health care and cost containment reforms, including government pricing and reimbursement policies; technological advances and patents obtained by competitors; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of strategic initiatives; the results of any pending or future litigations, investigations or claims; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; and Allergan's ability to obtain and successfully maintain a sufficient supply of products to meet market demand in a timely manner. In addition, matters generally affecting the economy, such as changes in interest and currency exchange rates; international relations; and the state of the economy worldwide can materially affect Allergan's results. Therefore, the reader is cautioned not to rely on these forward-looking statements. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.

Additional information concerning the above-referenced risk factors and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2006 Form 10-K and Allergan's Form 10-Q for the period ended June 29, 2007. Copies of Allergan's press releases and additional information about Allergan is available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 714-246-4636.

About Allergan, Inc.

With more than 55 years of experience providing high-quality, science-based products, Allergan, Inc., with headquarters in Irvine, California, discovers, develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention, urologics and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives.

(R) and (TM) Marks owned by Allergan, Inc.

ACULAR(R) is a registered trademark of Roche Palo Alto, LLC -0-

                            ALLERGAN, INC.

         Condensed Consolidated Statements of Operations and

                Reconciliation of Non-GAAP Adjustments

                             (Unaudited)



                                             Three months ended

                                        ------------------------------

In millions, except per share amounts        September 28, 2007

--------------------------------------- -----------------------------

                                                 Non-GAAP

                                         GAAP   Adjustments Adjusted

                                        ------- ----------- ---------

Revenues

 Product net sales                      $978.7      $--      $978.7

 Other revenues                           15.0       --        15.0

                                        ------- --------    ---------

                                         993.7       --       993.7


Operating costs and expenses

 Cost of sales (excludes amortization

  of acquired intangible assets)         173.5     (0.7)(a)   172.8

 Selling, general and administrative     395.6     (1.9)(b)   393.7

 Research and development                164.4       --       164.4

 Amortization of acquired intangible

  assets                                  28.7    (23.5)(c)     5.2

 Restructuring charges                    11.0    (11.0)(d)      --

                                        ------- --------    ---------


Operating income                         220.5     37.1       257.6


Non-operating income (expense)

 Interest income                          18.4       --        18.4

 Interest expense                        (17.5)      --       (17.5)

 Unrealized gain (loss) on derivative

  instruments, net                         0.4     (0.4)(e)      --

 Gain on investments                        --       --          --

 Other, net                              (10.5)      --       (10.5)

                                        ------- --------    ---------

                                          (9.2)    (0.4)       (9.6)

                                        ------- --------    ---------


Earnings from continuing operations

 before income taxes and minority

 interest                                211.3     36.7       248.0


Provision for income taxes                55.3     12.8 (f)    68.1

                                        ------- --------    ---------


Earnings from continuing operations      156.0     23.9       179.9


Discontinued operations:

 Earnings from discontinued operations,

  net of applicable income tax of $0.8

  million                                  1.4     (1.4)(g)      --

 Gain on sale of discontinued

  operations, net of tax of $0.9

  million                                   --       --          --

                                        ------- --------    ---------


Discontinued operations                    1.4     (1.4)         --


Net earnings                            $157.4    $22.5      $179.9

                                        ======= ========    =========


Basic earnings per share:

   Continuing operations                 $0.51                $0.59

   Discontinued operations                  --                   --

                                        -------             ---------

   Net basic earnings per share          $0.51                $0.59

                                        =======             =========


Diluted earnings per share:

   Continuing operations                 $0.50                $0.58

   Discontinued operations                0.01                   --

                                        -------             ---------

   Net diluted earnings per share        $0.51                $0.58

                                        =======             =========


Weighted average number of common

 shares outstanding:

   Basic                                 305.9                305.9

   Diluted                               309.3                309.3


Selected ratios as a percentage of

 product net sales

---------------------------------------


Selling, general and administrative       40.4%                40.2%

Research and development                  16.8%                16.8%


                                           Three months ended

                                   -----------------------------------

In millions, except per share

 amounts                                    September 29, 2006

-----------------------------------  ---------------------------------

                                                Non-GAAP

                                      GAAP     Adjustments   Adjusted

                                     ------- --------------- ---------

Revenues

 Product net sales                   $791.7    $--             $791.7

 Other revenues                        15.1     --               15.1

                                     ------- ------          ---------

                                      806.8     --              806.8


Operating costs and expenses

 Cost of sales (excludes

  amortization of acquired

  intangible assets)                  167.7  (24.1)(h)(i)       143.6

 Selling, general and

  administrative                      364.0  (33.6)(h)(j)(k)    330.4

 Research and development             120.4   (0.1)(j)          120.3

 Amortization of acquired

  intangible assets                    24.9  (19.6)(c)            5.3

 Restructuring charges                  8.6   (8.6)(d)             --

                                     ------- ------          ---------


Operating income                      121.2   86.0              207.2


Non-operating income (expense)

 Interest income                       12.8     --               12.8

 Interest expense                     (11.9)  (4.3)(l)          (16.2)

 Unrealized gain (loss) on

  derivative instruments, net           0.2   (0.2)(e)             --

 Gain on investments                    0.1     --                0.1

 Other, net                            (1.7)    --               (1.7)

                                     ------- ------          ---------

                                       (0.5)  (4.5)              (5.0)

                                     ------- ------          ---------


Earnings from continuing operations

 before income taxes and minority

 interest                             120.7   81.5              202.2


Provision for income taxes             14.3   43.1 (m)           57.4

                                     ------- ------          ---------


Earnings from continuing operations   106.4   38.4              144.8


Discontinued operations:

 Earnings from discontinued

  operations, net of applicable

  income tax of $0.8 million             --     --                 --

 Gain on sale of discontinued

  operations, net of tax of $0.9

  million                                --     --                 --

                                     ------- ------          ---------


Discontinued operations                  --     --                 --


Net earnings                         $106.4  $38.4             $144.8

                                     ======= ======          =========


Basic earnings per share:

   Continuing operations              $0.35                     $0.48

   Discontinued operations               --                        --

                                     -------                 ---------

   Net basic earnings per share       $0.35                     $0.48

                                     =======                 =========


Diluted earnings per share:

   Continuing operations              $0.35                     $0.47

   Discontinued operations               --                        --

                                     -------                 ---------

   Net diluted earnings per share     $0.35                     $0.47

                                     =======                 =========


Weighted average number of common

 shares outstanding:

   Basic                              301.8                     301.8

   Diluted                            305.1                     305.1


Selected ratios as a percentage of

 product net sales

-----------------------------------


Selling, general and administrative    46.0%                     41.7%

Research and development               15.2%                     15.2%

(a) Corneal fair market value inventory roll-out adjustment of $0.5 million and integration and transition costs related to the acquisition of Corneal and Inamed of $0.2 million

(b) Integration and transition costs related to the acquisitions of Corneal and Inamed of $1.2 million and $0.7 million, respectively

(c) Amortization of acquired intangible assets

(d) Net restructuring charges

(e) Unrealized gain (loss) on the mark-to-market adjustment to derivative instruments

(f) Total tax effect for non-GAAP pre-tax adjustments

(g) Discontinued operations

(h) Integration and transition costs related to the acquisition of Inamed, consisting of Cost of sales of $0.2 million and Selling, general and administrative expense of $4.9 million

(i) Inamed fair-market value inventory adjustment roll-out of $23.9 million

(j) Transition/duplicate operating expenses, consisting of Selling, general and administrative expense of $0.2 million and Research and development expense of $0.1 million

(k) Contribution to Allergan Foundation of $28.5 million

(l) Reversal of interest expense related to resolution of uncertain tax positions

(m) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): -0-

                                                            Tax effect

Non-GAAP pre-tax adjustments of $81.5 million                  $(27.8)

Resolution of uncertain tax positions                             3.9

Change in valuation allowance                                   (17.2)

Taxes related to intercompany transfers of trade businesses

 and net assets                                                   0.8

Change in estimated income taxes on 2005 dividend

 repatriation                                                    (2.8)

                                                            ----------

                                                               $(43.1)

                                                            ==========

"GAAP" refers to financial information presented in accordance with generally accepted accounting principles in the United States.

This press release includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission, with respect to the three and nine months ended September 28, 2007 and September 29, 2006 and with respect to anticipated results for the fourth quarter and full year of 2007. Allergan believes that its presentation of non-GAAP financial measures provides useful supplementary information to investors regarding its operational performance because it enhances an investor's overall understanding of the financial performance and prospects for the future of Allergan's core business activities by providing a basis for the comparison of results of core business operations between current, past and future periods. The presentation of historical non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.

In this press release, Allergan reported the non-GAAP financial measure "adjusted earnings" and related "adjusted diluted earnings per share." Allergan uses adjusted earnings to enhance the investor's overall understanding of the financial performance and prospects for the future of Allergan's core business activities. Adjusted earnings is one of the primary indicators management uses for planning and forecasting in future periods, including trending and analyzing the core operating performance of Allergan's business from period to period without the effect of the non-core business items indicated. Management uses adjusted earnings to prepare operating budgets and forecasts and to measure Allergan's performance against those budgets and forecasts on a corporate and segment level. Allergan also uses adjusted earnings for evaluating management performance for compensation purposes.

Despite the importance of adjusted earnings in analyzing Allergan's underlying business, the budgeting and forecasting process and designing incentive compensation, adjusted earnings has no standardized meaning defined by GAAP. Therefore, adjusted earnings has limitations as an analytical tool, and should not be considered in isolation, or as a substitute for analysis of Allergan's results as reported under GAAP. Some of these limitations are:

-- it does not reflect cash expenditures, or future requirements, for expenditures relating to restructurings, and certain acquisitions, including severance and facility transition costs associated with acquisitions;

-- it does not reflect gains or losses on the disposition of assets associated with restructuring and business exit activities;

-- it does not reflect the tax benefit or tax expense associated with the items indicated;

-- it does not reflect the impact on earnings of charges resulting from certain matters Allergan considers not to be indicative of its on-going operations; and

-- other companies in Allergan's industry may calculate adjusted earnings differently than it does, which may limit its usefulness as a comparative measure.

Allergan compensates for these limitations by using adjusted earnings only to supplement net income (loss) on a basis prepared in conformance with GAAP in order to provide a more complete understanding of the factors and trends affecting its business. Allergan strongly encourages investors to consider both net earnings (loss) and cash flows determined under GAAP as compared to adjusted earnings, and to perform their own analysis, as appropriate. -0-

                            ALLERGAN, INC.

         Condensed Consolidated Statements of Operations and

                Reconciliation of Non-GAAP Adjustments

                             (Unaudited)



                                            Nine months ended

                                     ---------------------------------

in millions, except per share

 amounts                                   September 28, 2007

------------------------------------ --------------------------------

                                                Non-GAAP

                                       GAAP    Adjustments Adjusted

                                     --------- ----------- ----------

Revenues

 Product net sales                   $2,803.9      $--     $2,803.9

 Other revenues                          44.4       --         44.4

                                     --------- --------    ----------

                                      2,848.3       --      2,848.3


Operating costs and expenses

 Cost of sales (excludes

  amortization of acquired

  intangible assets)                    493.4     (0.7)(a)    492.7

 Selling, general and administrative  1,215.1    (19.8)(b)  1,195.3

 Research and development               528.4    (72.0)(c)    456.4

 Amortization of acquired intangible

  assets                                 86.1    (70.0)(d)     16.1

 Restructuring charges                   24.3    (24.3)(e)       --

                                     --------- --------    ----------


Operating income                        501.0    186.8        687.8


Non-operating income (expense)

 Interest income                         48.6     (0.4)(f)     48.2

 Interest expense                       (53.5)      --        (53.5)

 Unrealized (loss) gain on

  derivative instruments, net            (1.3)     1.3 (g)       --

 Gain on investments                       --       --           --

 Other, net                             (15.9)      --        (15.9)

                                     --------- --------    ----------

                                        (22.1)     0.9        (21.2)


Earnings from continuing operations

 before income taxes and minority

 interest                               478.9    187.7        666.6


Provision for income taxes              138.7     39.7 (h)    178.4

Minority interest                         0.4       --          0.4

                                     --------- --------    ----------


Earnings from continuing operations     339.8    148.0        487.8


Discontinued operations:

 Loss from discontinued operations,

  net of applicable income tax

  benefit of $0.4 million                (0.8)     0.8 (i)       --

 Gain on sale of discontinued

  operations, net of tax of $0.9

  million                                  --       --           --

                                     --------- --------    ----------


Discontinued operations                  (0.8)     0.8           --


Net earnings                           $339.0   $148.8       $487.8

                                     ========= ========    ==========


Basic earnings per share:

   Continuing operations                $1.11                 $1.60

   Discontinued operations                 --                    --

                                     ---------             ----------

   Net basic earnings per share         $1.11                 $1.60

                                     =========             ==========


Diluted earnings per share:

   Continuing operations                $1.10                 $1.58

   Discontinued operations                 --                    --

                                     ---------             ----------

   Net diluted earnings per share       $1.10                 $1.58

                                     =========             ==========


Weighted average number of common

 shares outstanding:

   Basic                                304.9                 304.9

   Diluted                              308.3                 308.3


Selected ratios as a percentage of

 product net sales

------------------------------------


Selling, general and administrative      43.3%                 42.6%

Research and development                 18.8%                 16.3%


                                         Nine months ended

                              ----------------------------------------

in millions, except per share

 amounts                                 September 29, 2006

------------------------------  --------------------------------------

                                               Non-GAAP

                                  GAAP       Adjustments     Adjusted

                                --------- ------------------ ---------

Revenues

 Product net sales              $2,193.9       $--           $2,193.9

 Other revenues                     40.3        --               40.3

                                --------- ---------          ---------

                                 2,234.2        --            2,234.2


Operating costs and expenses

 Cost of sales (excludes

  amortization of acquired

  intangible assets)               433.2     (48.6)(j)(k)       384.6

 Selling, general and

  administrative                   975.4     (48.8)(j)(l)(m)    926.6

 Research and development          930.1    (580.0)(j)(l)(n)    350.1

 Amortization of acquired

  intangible assets                 54.8     (39.1)(d)           15.7

 Restructuring charges              17.1     (17.1)(e)             --

                                --------- ---------          ---------


Operating income                  (176.4)    733.6              557.2


Non-operating income (expense)

 Interest income                    34.3       4.9 (o)           39.2

 Interest expense                  (40.2)     (4.9)(o)          (45.1)

 Unrealized (loss) gain on

  derivative instruments, net       (1.0)      1.0 (g)             --

 Gain on investments                 0.3        --                0.3

 Other, net                         (7.1)      4.8 (p)           (2.3)

                                --------- ---------          ---------

                                   (13.7)      5.8               (7.9)


Earnings from continuing

 operations before income

 taxes and minority interest      (190.1)    739.4              549.3


Provision for income taxes          74.0      84.5 (q)          158.5

Minority interest                    0.1        --                0.1

                                --------- ---------          ---------


Earnings from continuing

 operations                       (264.2)    654.9              390.7


Discontinued operations:

 Loss from discontinued

  operations, net of

  applicable income tax

  benefit of $0.4 million             --        --                 --

 Gain on sale of discontinued

  operations, net of tax of

  $0.9 million                        --        --                 --

                                --------- ---------          ---------


Discontinued operations               --        --                 --


Net earnings                     $(264.2)   $654.9             $390.7

                                ========= =========          =========


Basic earnings per share:

   Continuing operations          $(0.91)                       $1.34

   Discontinued operations            --                           --

                                ---------                    ---------

   Net basic earnings per

    share                         $(0.91)                       $1.34

                                =========                    =========


Diluted earnings per share:

   Continuing operations          $(0.91)                       $1.32

   Discontinued operations            --                           --

                                ---------                    ---------

   Net diluted earnings per

    share                         $(0.91)                       $1.32

                                =========                    =========


Weighted average number of

 common shares outstanding:

   Basic                           290.7                        290.7

   Diluted                         290.7                        296.3


Selected ratios as a

 percentage of product net

 sales

------------------------------


Selling, general and

 administrative                     44.5%                        42.2%

Research and development            42.4%                        16.0%

(a) Corneal fair market value inventory roll-out adjustment of $0.5 million and integration and transition costs related to the acquisition of Corneal and Inamed of $0.2 million

(b) Integration and transition costs related to the acquisitions of Corneal and Inamed of $6.8 million and $4.3 million, respectively, settlement of an unfavorable pre-existing Corneal distribution contract for $2.3 million, and $6.4 million legal settlement of a patent dispute assumed in the Inamed acquisition

(c) In-process research and development charge related to the acquisition of EndoArt

(d) Amortization of acquired intangible assets

(e) Net restructuring charges

(f) Interest income related to income tax settlements

(g) Unrealized gain (loss) on the mark-to-market adjustment to derivative instruments

(h) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): -0-

Non-GAAP pre-tax adjustments of $187.7 million                 $(38.1)

Favorable recovery of previously paid state income taxes         (1.6)

                                                               -------

                                                               $(39.7)

                                                               =======

(i) Discontinued operations

(j) Integration and transition costs related to the acquisition of Inamed, consisting of Cost of sales of $0.7 million; Selling, general and administrative expense of $14.6 million and Research and development expense of $0.2 million

(k) Inamed fair-market value inventory adjustment roll-out of $47.9 million

(l) Transition/duplicate operating expenses, consisting of Selling, general and administrative expense of $5.7 million and Research and development expense of $0.5 million

(m) Contribution to Allergan Foundation of $28.5 million

(n) In-process research and development charge of $579.3 million related to the acquisition of Inamed

(o) Reversal of interest income on previously paid state income taxes and reversal of interest expense related to the resolution of uncertain tax positions

(p) Accrued costs for a previously disclosed contingency involving non-income taxes in Brazil

(q) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): -0-

                                                            Tax effect

Non-GAAP pre-tax adjustments of $739.4 million                 $(53.6)

Resolution of uncertain tax positions and favorable

 recovery of previously paid state income taxes                 (11.7)

Change in valuation allowance                                   (17.2)

Taxes related to intercompany transfers of trade businesses

 and net assets                                                   0.8

Change in estimated income taxes on 2005 dividend

 repatriation                                                    (2.8)

                                                            ----------

                                                               $(84.5)

                                                            ==========

-0-
                            ALLERGAN, INC.

                Condensed Consolidated Balance Sheets

                             (Unaudited)


                                            September 28, December 31,

in millions                                     2007          2006

------------------------------------------- ------------- ------------


Assets


Cash and equivalents                            $1,413.3     $1,369.4

Trade receivables, net                             478.3        386.9

Inventories                                        202.5        168.5

Other current assets                               322.6        205.5

                                            ------------- ------------


Total current assets                             2,416.7      2,130.3


Property, plant and equipment, net                 637.6        611.4

Intangible assets, net                           1,105.9      1,043.6

Goodwill, net                                    1,961.8      1,833.6

Other noncurrent assets                            175.5        148.2

                                            ------------- ------------


Total assets                                    $6,297.5     $5,767.1

                                            ============= ============



Liabilities and stockholders' equity


Notes payable                                      $39.6       $102.0

Accounts payable                                   187.8        142.4

Accrued expenses and income taxes                  416.1        413.7

                                            ------------- ------------


Total current liabilities                          643.5        658.1


Long-term debt                                   1,577.8      1,606.4

Other liabilities                                  470.1        359.5

Stockholders' equity                             3,606.1      3,143.1

                                            ------------- ------------


Total liabilities and stockholders' equity      $6,297.5     $5,767.1

                                            ============= ============


DSO                                                   45           43


DOH                                                  107          108


Cash, net of debt                                $(204.1)     $(339.0)


Debt-to-capital percentage                          31.0%        35.2%

-0-
                            ALLERGAN, INC.

             Reconciliation of Diluted Earnings Per Share

                             (Unaudited)


In millions, except per share amounts          Three months ended

------------------------------------------ ---------------------------

                                           September 28, September 29,

                                               2007          2006

                                           ------------- -------------


Earnings from continuing operations              $156.0        $106.4


Non-GAAP pre-tax adjustments:

   Net restructuring charges                       11.0           8.6

   Interest related to previously paid

    state income taxes and income tax

    settlements                                      --          (4.3)

   Amortization of acquired intangible

    assets                                         23.5          19.6

   Corneal integration and transition

    costs                                           1.3            --

   Inamed fair market-value inventory

    adjustment roll-out                              --          23.9

   Corneal fair market-value inventory

    adjustment roll-out                             0.5            --

   Inamed integration and transition costs          0.8           5.1

   Contribution to Allergan Foundation               --          28.5

   Unrealized (gain) loss on derivative

    instruments                                    (0.4)         (0.2)

   Transition/duplicate operating expenses           --           0.3

                                           ------------- -------------

                                                  192.7         187.9


Tax effect for above items                        (12.8)        (27.8)

Resolution of uncertain tax positions                --           3.9

Tax effect of dividend repatriation act              --          (2.8)

Taxes related to intercompany transfers of

 trade businesses and net assets                     --           0.8

Change in valuation allowance                        --         (17.2)

                                           ------------- -------------


Adjusted diluted earnings from continuing

 operations                                      $179.9        $144.8

                                           ============= =============



Weighted average number of shares issued          305.9         301.8


Net shares assumed issued using the

 treasury stock method for options and

 non-vested equity shares and share units

 outstanding during each period based on

 average market price                               3.4           3.3

                                           ------------- -------------


                                                  309.3         305.1

                                           ============= =============




Diluted earnings per share from continuing

 operations, as reported                          $0.50         $0.35


   Non-GAAP earnings per share

    adjustments:

   Net restructuring charges                       0.03          0.02

   Interest related to previously paid

    state income taxes and income tax

    settlements                                      --         (0.01)

   Amortization of acquired intangible

    assets                                         0.05          0.04

   Corneal integration and transition

    costs                                            --            --

   Inamed fair market-value inventory

    adjustment roll-out                              --          0.05

   Corneal fair market-value inventory

    adjustment roll-out                              --            --

   Inamed integration and transition costs           --          0.01

   Contribution to Allergan Foundation               --          0.06

   Unrealized (gain) loss on derivative

    instruments                                      --            --

   Resolution of uncertain tax positions             --          0.01

   Tax effect of dividend repatriation               --         (0.01)

   Change in valuation allowance                     --         (0.05)

                                           ------------- -------------


Adjusted diluted earnings per share from

 continuing operations                            $0.58         $0.47

                                           ============= =============


Year over year change                                 23.4%

                                           ===========================

-0-
                            ALLERGAN, INC.

             Reconciliation of Diluted Earnings Per Share

                             (Unaudited)


In millions, except per share amounts           Nine months ended

------------------------------------------ ---------------------------

                                           September 28, September 29,

                                               2007          2006

                                           ------------- -------------


Earnings (loss) from continuing operations       $339.8       $(264.2)


Non-GAAP pre-tax adjustments:

   Net restructuring charges                       24.3          17.1

   In-process research and development

    charge related to EndoArt                      72.0            --

   In-process research and development

    charge related to Inamed                         --         579.3

   Amortization of acquired intangible

    assets                                         70.0          39.1

   Settlement of unfavorable Corneal

    distribution contract                           2.3            --

   Corneal integration and transition

    costs                                           6.9            --

   Inamed fair market-value inventory

    adjustment roll-out                              --          47.9

   Corneal fair market-value inventory

    adjustment roll-out                             0.5            --

   Inamed integration and transition costs          4.4          15.5

   Legal settlement of patent dispute               6.4            --

   Contribution to Allergan Foundation               --          28.5

   Accrued costs for a previously

    disclosed contingency involving non-

    income taxes in Brazil                           --           4.8

   Interest related to previously paid

    state income taxes and resolution of

    uncertain tax positions                        (0.4)           --

   Unrealized (gain) loss on derivative

    instruments                                     1.3           1.0

   Transition/duplicate operating expenses           --           6.2

                                           ------------- -------------

                                                  527.5         475.2


Tax effect for above items                        (38.1)        (53.6)

Resolution of uncertain tax positions                --         (10.5)

Tax effect of dividend repatriation act              --          (2.8)

Taxes related to intercompany transfers of

 trade businesses and net assets                     --           0.8

Change in valuation allowance                        --         (17.2)

State income tax recovery                          (1.6)         (1.2)

                                           ------------- -------------


Adjusted diluted earnings from continuing

 operations                                      $487.8        $390.7

                                           ============= =============



Weighted average number of shares issued          304.9         290.7


Net shares assumed issued using the

 treasury stock method for options and

 non-vested equity shares and share units

 outstanding during each period based on

 average market price                               3.4           3.4


Dilutive effect of assumed conversion of

 convertible notes outstanding                       --           2.2

                                           ------------- -------------


                                                  308.3         296.3

                                           ============= =============


Diluted earnings (loss) per share from

 continuing operations, as reported               $1.10        $(0.91)


Effect of additional dilutive shares (a)             --          0.02


Non-GAAP earnings per share adjustments:

   Net restructuring charges                       0.06          0.05

   In-process research and development

    charge related to EndoArt                      0.23            --

   In-process research and development

    charge related to Inamed                         --          1.96

   Amortization of acquired intangible

    assets                                         0.15          0.09

   Settlement of unfavorable Corneal

    distribution contract                          0.01            --

   Corneal integration and transition

    costs                                          0.02            --

   Inamed fair market-value inventory

    adjustment roll-out                              --          0.11

   Corneal fair market-value inventory

    adjustment roll-out                              --            --

   Inamed integration and transition costs         0.01          0.03

   Legal settlement of patent dispute              0.01            --

   Contribution to Allergan Foundation               --          0.06

   Accrued costs for a previously

    disclosed contingency involving non-

    income taxes in Brazil                           --          0.01

   Interest related to previously paid

    state income taxes and resolution of

    uncertain tax positions                          --            --

   Unrealized (gain) loss on derivative

    instruments                                      --            --

   Transition/duplicate operating expenses           --          0.01

   Resolution of uncertain tax positions             --         (0.04)

   Tax effect of dividend repatriation               --         (0.01)

   Change in valuation allowance                     --         (0.06)

   State income tax recovery                      (0.01)           --

                                           ------------- -------------


Adjusted diluted earnings per share from

 continuing operations                            $1.58         $1.32

                                           ============= =============


Year over year change                                 19.7%

                                           ===========================

(a) The number of shares used to calculate adjusted diluted earnings per share includes the dilutive effect of outstanding stock options and the assumed conversion of convertible notes. -0-

                            ALLERGAN, INC.

                   Supplemental Non-GAAP Information

                              (Unaudited)

                            ($ in millions)



                      Three months ended

                      -------------------

                      Sept. 28, Sept. 29,    $ change in net sales

                                          ----------------------------

                        2007      2006     Total  Performance Currency

                      --------- --------- ------- ----------- --------

Eye Care

 Pharmaceuticals        $457.7    $403.4   $54.3       $42.9     $11.4

Botox/Neuromodulator     296.7     237.7    59.0        52.4       6.6

Skin Care                 29.5      34.3    (4.8)       (4.8)       --

                      --------- --------- ------- ----------- --------

  Total Specialty

   Pharmaceuticals       783.9     675.4   108.5        90.5      18.0


Breast Aesthetics         69.7      54.1    15.6        13.5       2.1

Obesity Intervention      74.0      47.1    26.9        25.8       1.1

Facial Aesthetics         49.3      15.1    34.2        33.6       0.6

                      --------- --------- ------- ----------- --------

  Core Medical

   Devices               193.0     116.3    76.7        72.9       3.8


Other                      1.8        --     1.8         1.8        --

                      --------- --------- ------- ----------- --------


  Total Medical

   Devices               194.8     116.3    78.5        74.7       3.8


Product net sales       $978.7    $791.7  $187.0      $165.2     $21.8

                      ========= ========= ======= =========== ========


Alphagan P, Alphagan,

 and Combigan            $89.8     $80.0    $9.8        $7.4      $2.4

Lumigan Franchise        100.4      86.4    14.0        11.2       2.8

Other Glaucoma             3.9       3.4     0.5         0.2       0.3

Restasis                  88.2      69.3    18.9        18.9        --


Domestic                  65.4%     68.1%   NA        NA         NA

International             34.6%     31.9%   NA        NA         NA



                                          Percent change in net sales

                                          ----------------------------

                                           Total  Performance Currency

                                          ------- ----------- --------

Eye Care Pharmaceuticals                   13.5%       10.6%      2.9%

Botox/Neuromodulator                       24.8%       22.0%      2.8%

Skin Care                                 (14.0)%     (14.0)%     0.0%

  Total Specialty Pharmaceuticals          16.1%       13.4%      2.7%


Breast Aesthetics                          28.8%       25.0%      3.8%

Obesity Intervention                       57.1%       54.8%      2.3%

Facial Aesthetics                         226.5%      222.5%      4.0%

  Core Medical Devices                     66.0%       62.7%      3.3%


Other                                       NA        NA         NA


  Total Medical Devices                    67.5%       64.2%      3.3%


Product net sales                          23.6%       20.9%      2.7%


Alphagan P, Alphagan, and Combigan         12.2%        9.3%      2.9%

Lumigan Franchise                          16.2%       13.0%      3.2%

Other Glaucoma                             14.8%        7.3%      7.5%

Restasis                                   27.3%       27.3%      0.0%


Domestic                                    NA        NA         NA

International                               NA        NA         NA

-0-
                       Nine months ended

                      -------------------

                      Sept. 28, Sept. 29,    $ change in net sales

                                          ----------------------------

                        2007      2006     Total  Performance Currency

                      --------- --------- ------- ----------- --------

Eye Care

 Pharmaceuticals      $1,292.1  $1,144.5  $147.6      $119.6     $28.0

Botox/Neuromodulator     872.0     709.1   162.9       146.7      16.2

Skin Care                 82.7      95.7   (13.0)      (13.0)       --

                      --------- --------- ------- ----------- --------

  Total Specialty

   Pharmaceuticals     2,246.8   1,949.3   297.5       253.3      44.2


Breast Aesthetics        217.8     118.7    99.1        94.9       4.2

Obesity Intervention     195.9      92.9   103.0       101.0       2.0

Facial Aesthetics        141.6      33.0   108.6       107.4       1.2

                      --------- --------- ------- ----------- --------

  Core Medical

   Devices               555.3     244.6   310.7       303.3       7.4


Other                      1.8        --     1.8         1.8        --

                      --------- --------- ------- ----------- --------


  Total Medical

   Devices               557.1     244.6   312.5       305.1       7.4


Product net sales     $2,803.9  $2,193.9  $610.0      $558.4     $51.6

                      ========= ========= ======= =========== ========


Alphagan P, Alphagan,

 and Combigan           $244.8    $221.2   $23.6       $17.5      $6.1

Lumigan Franchise        284.0     241.0    43.0        35.5       7.5

Other Glaucoma            11.4      12.0    (0.6)       (1.3)      0.7

Restasis                 243.9     201.0    42.9        42.9        --


Domestic                  65.7%     67.6%   NA        NA         NA

International             34.3%     32.4%   NA        NA         NA



                                          Percent change in net sales

                                          ----------------------------

                                           Total  Performance Currency

                                          ------- ----------- --------

Eye Care Pharmaceuticals                   12.9%       10.4%      2.5%

Botox/Neuromodulator                       23.0%       20.7%      2.3%

Skin Care                                 (13.6)%     (13.6)%     0.0%

  Total Specialty Pharmaceuticals          15.3%       13.0%      2.3%


Breast Aesthetics                          83.5%       79.9%      3.6%

Obesity Intervention                      110.9%      108.7%      2.2%

Facial Aesthetics                         329.1%      325.5%      3.6%

  Core Medical Devices                    127.0%      124.0%      3.0%


Other                                       NA        NA         NA


  Total Medical Devices                   127.8%      124.7%      3.1%


Product net sales                          27.8%       25.5%      2.3%


Alphagan P, Alphagan, and Combigan         10.6%        7.9%      2.7%

Lumigan Franchise                          17.8%       14.7%      3.1%

Other Glaucoma                             (5.0)%     (10.6)%     5.6%

Restasis                                   21.4%       21.4%      0.0%


Domestic                                    NA        NA         NA

International                               NA        NA         NA

-0-
                            ALLERGAN, INC.

      Reconciliation of GAAP Diluted Earnings Per Share Guidance

           To Adjusted Diluted Earnings Per Share Guidance

                             (Unaudited)


                                                       Quarter 4, 2007

                                                       ---------------

                                                         Low     High

                                                       -------- ------


GAAP diluted earnings per share from continuing

 operations guidance (a)                                 $0.51  $0.52


    Amortization of acquired intangible assets            0.05   0.05

                                                       -------- ------

Adjusted diluted earnings per share guidance             $0.56  $0.57

                                                       ======== ======



                                                       Full Year 2007

                                                       ---------------

                                                         Low     High

                                                       -------- ------


GAAP diluted earnings per share from continuing

 operations guidance (a)                                 $1.63  $1.64


    In-process research and development                   0.23   0.23

    Net restructuring charges                             0.06   0.06

    Settlement of unfavorable Corneal distribution

     contract                                             0.01   0.01

    Corneal and Inamed integration and transition

     costs                                                0.02   0.02

    Legal settlement of patent dispute                    0.01   0.01

    State income tax recovery                            (0.01) (0.01)

    Amortization of acquired intangible assets            0.19   0.19

                                                       -------- ------

Adjusted diluted earnings per share guidance             $2.14  $2.15

                                                       ======== ======

(a) GAAP diluted earnings per share guidance excludes any potential impact of future unrealized gains or losses on derivative instruments, restructuring charges and integration and transition costs that may occur but that are not currently known or determinable. -0-

                            ALLERGAN, INC.

                 Recasted for Discontinued Operations

         Condensed Consolidated Statements of Operations and

                Reconciliation of Non-GAAP Adjustments

                             (Unaudited)


                                               Three months ended

in millions, except per share amounts            March 30, 2007

----------------------------------------- ----------------------------

                                                   Non-GAAP

       

Posted: November 2007


View comments

Hide
(web4)